Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Cartesian Therapeutics, Inc.SELB · Entity 6015 | Director | June 15, 2018 | June 19, 2018 |
| Decoy Therapeutics Inc.FLKS · Entity 937 | Director | July 25, 2018 | July 26, 2018 |
| Moderna, Inc.MRNA · Entity 2025 | Director | November 20, 2019 | November 22, 2019 |
| XOMA Royalty CorpXOMA · Entity 30207 | Director | February 10, 2017 | May 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Cartesian Therapeutics, Inc.
Report date June 15, 2018 · Filed June 19, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.75 · Expires 2028-06-14 | Direct | 10,000 |
Reported balance
After 2018-06-15 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-06-15 · Grant · Acquired 10,000 · Balance 10,000 F1: The option vests in full on the earlier of June 15, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests in full on the earlier of June 15, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders.
Decoy Therapeutics Inc.
Report date July 25, 2018 · Filed July 26, 2018
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.82 · Expires 2028-07-25 | Direct | 10,000 |
Reported balance
After 2018-07-25 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2018-07-25 · Grant · Acquired 10,000 · Balance 10,000 F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018.
Moderna, Inc.
Report date November 20, 2019 · Filed November 22, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 3,924 |
Ending reported balance
After 2019-11-20 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2019-11-20 · Exercise / conversion · Acquired 200,000 · Balance 203,924 Row 2 · 2019-11-20 · Sale · Disposed 200,000 · Balance 3,924 F1: The price reported in Column 4 is a weighted average price. The shares sold in multiple transactions at prices ranging from $20.00 to $20.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.04 · Expires 2022-03-27 | Direct | 502,752 |
Reported balance
After 2019-11-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2019-11-20 · Exercise / conversion · Disposed 200,000 · Balance 502,752 F2: This option is fully vested and exercisable. |
Filing footnotes · ownership attribution and instrument terms
F1: The price reported in Column 4 is a weighted average price. The shares sold in multiple transactions at prices ranging from $20.00 to $20.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F2: This option is fully vested and exercisable.
XOMA Royalty Corp
Report date February 10, 2017 · Filed May 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Non-Qualified Share Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.03 · Expires 2027-02-10 | Direct | 8,000 |
Reported balance
After 2017-02-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-10 · Grant · Acquired 8,000 · Balance 8,000 F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017.
F2: Shares subject to this option shall vest in equal monthly installments over three years from the grant date.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CONCERT PHARMACEUTICALS, INC.
Report date March 06, 2023 · Filed March 06, 2023
Section 16 reporting ended · disclosed 2023-03-06. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2023-03-06 · Other · Disposed 13,088 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2) F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2023-03-06 · Disposition to issuer · Disposed 16,400 · Balance 0 F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.42 · Expires 2025-06-10 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.96 · Expires 2026-06-08 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $13.29 · Expires 2027-06-14 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.59 · Expires 2028-06-13 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $11.02 · Expires 2029-06-12 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.16 · Expires 2030-06-10 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2023-03-06 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.26 · Expires 2031-06-09 | Direct | 0 |
Reported balance
After 2023-03-06 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2023-03-06 · Disposition to issuer · Disposed 10,250 · Balance 0 F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2)
F2: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest.
F3: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest.
F4: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5)
F5: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment.
IMMUNOMEDICS INC
Report date October 23, 2020 · Filed October 23, 2020
Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Disposition to issuer · Disposed 13,516 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-23 · Disposition to issuer · Disposed 52,614 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0 F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,250 | Not disclosed Strike: $4.26 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 9 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,250 shares Expires 2031-06-09 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $9.16 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 8 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $11.02 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 7 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $19.59 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 6 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $13.29 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 5 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $12.96 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 4 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2026-06-08 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,000 | Not disclosed Strike: $16.42 | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,000 shares Expires 2025-06-10 F4 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · price: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. F4 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option that had a per share exercise price that was less than the Cash Amount (whether vested or unvested) that was outstanding and unexercised immediately prior to the Effective Time, was cancelled and converted into the right to receive, for each Share underlying such option, (i) an amount in cash equal to the excess of the Cash Amount over the per share exercise price of such option and (ii) one CVR. Each option that was outstanding and unexercised immediately prior to the Effective Time that had a per share exercise price greater than or equal to the Cash Amount, and less than $11.50, was cancelled and converted into the right to receive, for each Share underlying such option, upon the occurrence of any Milestone Payment, (i) an amount in cash equal to the Cash Amount, plus the applicable Milestone Payment, plus any Milestone Payment previously paid with respect to such Share, (continued in Footnote 5) F5 · derivative.exercise_date: minus the per share exercise price of the option, minus (ii) any amount previously paid out for such option pursuant to any previous Milestone Payment. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Disposition to issuerCommon Stock | 16,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F3 · shares: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. F3 · price: This line item represents unvested time-based restricted stock units with respect to the Issuer's common stock ("RSUs") held by the Reporting Person. Pursuant to the terms of the Merger Agreement, at the Effective Time, each unvested RSU that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive, for each Share underlying such RSU, the Per Share Consideration, subject to withholding of applicable taxes and without interest. Read SEC document |
| March 06, 2023 Filed Mar 6, 2023 11:38 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | OtherCommon Stock | 13,088 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-016165 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 19, 2023, by and among Concert Pharmaceuticals, Inc. (the "Issuer"), Sun Pharmaceutical Industries Ltd. ("Parent") and Foliage Merger Sub, Inc., an indirect wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of March 6, 2023 (the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive $8.00 in cash (the "Cash Amount"), plus one non-tradeable contingent value right (a "CVR," and together with the Cash Amount, the "Per Share Consideration"), which represents the right to receive contingent payments of up to $3.50 per Share, in cash, (continued in Footnote 2) F2 · price: in the aggregate, upon the achievement of certain milestones (such applicable payment, each, a "Milestone Payment") prior to December 31, 2029, subject to any applicable withholding of taxes and without interest. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 16:25 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionStock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $2.88 | $0.00 |
DisclosureSEC source: 0001209191-22-053967 · doc4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2022-11-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 16:25 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | SaleCommon Stock | 3,539 | $6.09 | $21,552.51 |
DisclosureSEC source: 0001209191-22-053967 · doc4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,488 Read SEC document |
| October 14, 2022 Filed Oct 18, 2022 16:25 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $2.88 | $10,192.32 |
DisclosureSEC source: 0001209191-22-053967 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,027 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 09, 2022 Filed Jun 13, 2022 16:15 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 16,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-036288 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,488 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 9, 2023 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2 · price: Not applicable. Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:41 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,250 | $0.00 Strike: $4.26 | $0.00 |
DisclosureSEC source: 0001209191-21-039746 · doc4.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,250 Underlying: Common Stock · 10,250 shares Expires 2031-06-09 F3 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 10, 2022, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 10, 2022). Read SEC document |
| June 10, 2021 Filed Jun 11, 2021 08:41 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantCommon Stock | 5,125 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-039746 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,088 F1 · shares: Represents a grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. These RSUs vest in full on the earlier of (i) June 10, 2022 and (ii) the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders. The amount listed represents the maximum number of shares of Common Stock of the Issuer that may be delivered pursuant to the grant. F2 · price: Not applicable. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 17:34 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | Disposition to issuerRestricted Stock Unit · Derivative | 3,718 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-117801 · a4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,718 shares Expires not disclosed F3 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · price: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. F3 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 17:34 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | Disposition to issuerStock Option (Right to Buy) · Derivative | 52,614 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-117801 · a4.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 52,614 shares Expires not disclosed F2 · derivative.exercise_price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · price: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.exercise_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. F2 · derivative.expiration_date: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. Read SEC document |
| October 23, 2020 Filed Oct 23, 2020 17:34 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | Disposition to issuerCommon Stock | 13,516 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-20-117801 · a4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · shares: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. F1 · price: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 16:01 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionStock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001209191-20-048893 · doc4.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2020-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 31, 2020 Filed Sep 1, 2020 16:01 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $3.79 | $13,412.81 |
DisclosureSEC source: 0001209191-20-048893 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 17:20 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 6,540 | $0.00 Strike: $33.62 | $0.00 |
DisclosureSEC source: 0001104659-20-075696 · a4.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,540 Underlying: Common Stock, par value $0.01 per share · 6,540 shares Expires 2030-06-18 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| June 18, 2020 Filed Jun 22, 2020 17:20 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantCommon Stock, $0.01 par value per share | 3,718 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-20-075696 · a4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,234 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2020 annual meeting of stockholders, which occurred on June 18, 2020. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| June 11, 2020 Filed Jun 12, 2020 17:04 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $9.16 | $0.00 |
DisclosureSEC source: 0001209191-20-036348 · doc4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2030-06-10 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period through June 11, 2021, provided that such option shall vest in full on the date that is one business day prior to the date of the Issuer's next annual meeting of stockholders (if earlier than June 11, 2021). Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 06:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 200,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001127602-19-033520 · form4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 502,752 Underlying: Common Stock · 200,000 shares Expires 2022-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 06:23 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 200,000 | $20.18 | $4,036,000.00 |
DisclosureSEC source: 0001127602-19-033520 · form4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,924 F1 · price: The price reported in Column 4 is a weighted average price. The shares sold in multiple transactions at prices ranging from $20.00 to $20.34. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| November 20, 2019 Filed Nov 22, 2019 06:23 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 200,000 | $0.04 | $8,000.00 |
DisclosureSEC source: 0001127602-19-033520 · form4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 203,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 16:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.04 | $0.00 |
DisclosureSEC source: 0001127602-19-028728 · form4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 702,752 Underlying: Common Stock · 100,000 shares Expires 2022-03-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested and exercisable. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 16:11 UTC | Moderna, Inc. MRNA · Entity 2025 | SaleCommon Stock | 100,000 | $17.63 | $1,763,000.00 |
DisclosureSEC source: 0001127602-19-028728 · form4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,924 F1 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $17.31 to $17.94. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. Read SEC document |
| September 17, 2019 Filed Sep 18, 2019 16:11 UTC | Moderna, Inc. MRNA · Entity 2025 | Exercise / conversionCommon Stock | 100,000 | $0.04 | $4,000.00 |
DisclosureSEC source: 0001127602-19-028728 · form4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 103,924 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 16:00 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 3,539 | $0.00 Strike: $4.41 | $0.00 |
DisclosureSEC source: 0001209191-19-045483 · doc4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,539 shares Expires 2019-12-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 16:00 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | SaleCommon Stock | 3,539 | $10.31 | $36,487.09 |
DisclosureSEC source: 0001209191-19-045483 · doc4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,424 Read SEC document |
| August 08, 2019 Filed Aug 12, 2019 16:00 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 3,539 | $4.41 | $15,606.99 |
DisclosureSEC source: 0001209191-19-045483 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,963 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 27, 2019 Filed Jun 28, 2019 16:14 UTC | Moderna, Inc. MRNA · Entity 2025 | GrantStock Option (Right to Buy) · Derivative | 54,660 | $0.00 Strike: $14.34 | $0.00 |
DisclosureSEC source: 0001127602-19-023015 · form4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 54,660 Underlying: Common Stock · 54,660 shares Expires 2029-06-27 F1 · derivative.exercise_date: This option will become fully vested and exercisable on the earlier of June 27, 2020, or the next Annual Meeting of Stockholders, subject to the recipient's continued service. Read SEC document |
| June 13, 2019 Filed Jun 17, 2019 21:06 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $11.02 | $0.00 |
DisclosureSEC source: 0001209191-19-037564 · doc4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2029-06-12 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 13, 2020. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 16:29 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Option (right to buy) · Derivative | 17,077 | $0.00 Strike: $12.93 | $0.00 |
DisclosureSEC source: 0001104659-19-034788 · a4.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,077 Underlying: Common Stock, par value $0.01 per share · 17,077 shares Expires 2026-06-07 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| June 07, 2019 Filed Jun 11, 2019 16:29 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantCommon Stock, $0.01 par value per share | 9,667 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-19-034788 · a4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,516 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2019 annual meeting of stockholders, which occurred on June 7, 2019. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| July 25, 2018 Filed Jul 26, 2018 15:52 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $0.82 | $0.00 |
DisclosureSEC source: 0001615219-18-000043 · wf-form4_153263472568123.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-07-25 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from June 6, 2018. Read SEC document |
| June 15, 2018 Filed Jun 19, 2018 19:03 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $12.75 | $0.00 |
DisclosureSEC source: 0001638599-18-000674 · doc4_5484.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-14 F1 · derivative.exercise_date: The option vests in full on the earlier of June 15, 2019 or the day immediately prior to the company's 2019 annual meeting of shareholders. Read SEC document |
| June 14, 2018 Filed Jun 18, 2018 18:59 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $19.59 | $0.00 |
DisclosureSEC source: 0000899243-18-017079 · doc4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2028-06-13 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 14, 2019. Read SEC document |
| April 02, 2018 Filed Sep 18, 2018 14:54 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Options (right to buy) · Derivative | 6,497 | $0.00 Strike: $14.29 | $0.00 |
DisclosureSEC source: 0001171843-18-006603 · ownership.xml · derivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock, par value $0.01 per share · 6,497 shares Expires 2025-04-02 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F3 · derivative.exercise_date: The stock options vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| April 02, 2018 Filed Sep 18, 2018 14:54 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantCommon Stock, $0.01 par value per share | 3,849 | $0.00 | $0.00 |
DisclosureSEC source: 0001171843-18-006603 · ownership.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,849 F1 · date: Such grants of restricted stock units and stock options were made automatically pursuant to the Issuer's compensation policy for non-employee directors as of the date of the Issuer's 2018 annual meeting of stockholders, which occurred on April 2, 2018. F2 · shares: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. F2 · balance_after: Includes restricted stock units that represent a contingent right to receive one share of the Issuer's common stock. The restricted stock units shall vest on the first anniversary of the date of grant, subject to the Reporting Person's continued service as a director of the Issuer. Read SEC document |
| July 26, 2017 Filed Jul 27, 2017 08:50 UTC | Decoy Therapeutics Inc. FLKS · Entity 937 | GrantStock Option (right to buy) · Derivative | 12,000 | $0.00 Strike: $4.08 | $0.00 |
DisclosureSEC source: 0001615219-17-000050 · wf-form4_150115980932435.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,000 Underlying: Common Stock · 12,000 shares Expires 2027-07-26 F1 · derivative.exercise_date: The stock option will vest in 12 successive equal monthly installments measured from July 26, 2017. Read SEC document |
| July 03, 2017 Filed Jul 6, 2017 18:05 UTC | IMMUNOMEDICS INC IMMU · Entity 145732 | GrantStock Options (right to buy) · Derivative | 22,500 | $0.00 Strike: $9.02 | $0.00 |
DisclosureSEC source: 0001104659-17-043900 · a4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,500 Underlying: Common Stock, par value $0.01 per share · 22,500 shares Expires 2024-07-03 Read SEC document |
| June 16, 2017 Filed Jun 20, 2017 16:42 UTC | Cartesian Therapeutics, Inc. SELB · Entity 6015 | GrantStock Option (Right to Buy) · Derivative | 6,410 | $0.00 Strike: $17.47 | $0.00 |
DisclosureSEC source: 0001638599-17-000640 · doc4_4810.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,410 Underlying: Common Stock · 6,410 shares Expires 2027-06-15 F1 · derivative.exercise_date: The option vests in full on the earlier of June 16, 2018 or the day immediately prior to the company's 2018 annual meeting of shareholders. Read SEC document |
| June 15, 2017 Filed Jun 19, 2017 07:28 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | GrantNonstatutory Stock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $13.29 | $0.00 |
DisclosureSEC source: 0001209191-17-040706 · doc4.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2027-06-14 F1 · derivative.exercise_date: The shares underlying this option vest in equal quarterly installments over a one-year period, through and including June 15, 2018. Read SEC document |
| February 10, 2017 Filed May 22, 2017 22:38 UTC | XOMA Royalty Corp XOMA · Entity 30207 | GrantNon-Qualified Share Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.03 | $0.00 |
DisclosureSEC source: 0000791908-17-000023 · edgardoc.xml · derivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 Underlying: Common Shares · 8,000 shares Expires 2027-02-10 F1 · date: This option was approved by the Board of Directors of the Issuer on February 10, 2017, subject to approval by the Issuer's stockholders, at the 2017 Annual Meeting of Stockholders, of an amendment of the Issuer's 2010 Long Term Incentive and Stock Award Plan (the "Plan"), including an increase in the number of shares reserved for issuance under the Plan (the "Amendment"). The Stockholders of the Issuer approved the Amendment on May 18, 2017. F2 · derivative.exercise_date: Shares subject to this option shall vest in equal monthly installments over three years from the grant date. Read SEC document |
| November 14, 2016 Filed Nov 21, 2016 16:10 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionNon-qualified Stock Option (right to buy) · Derivative | 22,123 | $0.00 Strike: $1.13 | $0.00 |
DisclosureSEC source: 0001209191-16-151428 · doc4.xml · derivative · entry 3 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 22,123 shares Expires 2017-06-04 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option is fully vested. Read SEC document |
| November 14, 2016 Filed Nov 21, 2016 16:10 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | SaleCommon Stock | 22,123 | $9.81 | $217,026.63 |
DisclosureSEC source: 0001209191-16-151428 · doc4.xml · nonDerivative · entry 2 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| November 14, 2016 Filed Nov 21, 2016 16:10 UTC | CONCERT PHARMACEUTICALS, INC. CNCE · Entity 115906 | Exercise / conversionCommon Stock | 22,123 | $1.13 | $24,998.99 |
DisclosureSEC source: 0001209191-16-151428 · doc4.xml · nonDerivative · entry 1 HUTT PETER BARTON · CIK 0001171527 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,123 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.